JP2014518884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518884A5 JP2014518884A5 JP2014512837A JP2014512837A JP2014518884A5 JP 2014518884 A5 JP2014518884 A5 JP 2014518884A5 JP 2014512837 A JP2014512837 A JP 2014512837A JP 2014512837 A JP2014512837 A JP 2014512837A JP 2014518884 A5 JP2014518884 A5 JP 2014518884A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- het
- atoms
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488997P | 2011-05-23 | 2011-05-23 | |
| US61/488,997 | 2011-05-23 | ||
| PCT/US2012/032983 WO2012161877A1 (en) | 2011-05-23 | 2012-04-11 | Pyridine-and pyrazine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016124235A Division JP2016196492A (ja) | 2011-05-23 | 2016-06-23 | ピリジン−及びピラジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518884A JP2014518884A (ja) | 2014-08-07 |
| JP2014518884A5 true JP2014518884A5 (OSRAM) | 2016-11-24 |
| JP6054954B2 JP6054954B2 (ja) | 2016-12-27 |
Family
ID=45976540
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512837A Expired - Fee Related JP6054954B2 (ja) | 2011-05-23 | 2012-04-11 | ピリジン−及びピラジン誘導体 |
| JP2016124235A Pending JP2016196492A (ja) | 2011-05-23 | 2016-06-23 | ピリジン−及びピラジン誘導体 |
| JP2018061990A Expired - Fee Related JP6763904B2 (ja) | 2011-05-23 | 2018-03-28 | ピリジン−及びピラジン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016124235A Pending JP2016196492A (ja) | 2011-05-23 | 2016-06-23 | ピリジン−及びピラジン誘導体 |
| JP2018061990A Expired - Fee Related JP6763904B2 (ja) | 2011-05-23 | 2018-03-28 | ピリジン−及びピラジン誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9273029B2 (OSRAM) |
| EP (1) | EP2714677B1 (OSRAM) |
| JP (3) | JP6054954B2 (OSRAM) |
| KR (1) | KR101581522B1 (OSRAM) |
| CN (1) | CN103748086B (OSRAM) |
| AU (1) | AU2012259333B2 (OSRAM) |
| BR (1) | BR112013029640A2 (OSRAM) |
| CA (1) | CA2832605C (OSRAM) |
| DK (1) | DK2714677T3 (OSRAM) |
| EA (1) | EA023364B1 (OSRAM) |
| ES (1) | ES2699256T3 (OSRAM) |
| HR (1) | HRP20181884T1 (OSRAM) |
| IL (1) | IL229528A (OSRAM) |
| LT (1) | LT2714677T (OSRAM) |
| MX (1) | MX352975B (OSRAM) |
| PL (1) | PL2714677T3 (OSRAM) |
| PT (1) | PT2714677T (OSRAM) |
| RS (1) | RS58015B1 (OSRAM) |
| SG (1) | SG194105A1 (OSRAM) |
| SI (1) | SI2714677T1 (OSRAM) |
| WO (1) | WO2012161877A1 (OSRAM) |
| ZA (1) | ZA201307429B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013029640A2 (pt) * | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
| GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| NZ717552A (en) * | 2013-08-07 | 2021-07-30 | Merck Patent Gmbh | Piperidine urea derivatives |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| AU2014361800B2 (en) | 2013-12-13 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| CA2939164A1 (en) * | 2014-02-12 | 2015-08-20 | Iteos Therapeutics | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
| MD20160118A2 (ro) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| EP3517536B1 (en) | 2014-09-26 | 2021-05-05 | Gilead Sciences, Inc. | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| US9994547B2 (en) | 2014-10-06 | 2018-06-12 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of TBK1 |
| EP3209648B1 (en) | 2014-10-22 | 2020-03-11 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| KR102013512B1 (ko) | 2015-03-17 | 2019-08-22 | 화이자 인코포레이티드 | 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법 |
| CA2994917A1 (en) | 2015-08-10 | 2017-02-16 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| JP2019500368A (ja) | 2015-12-17 | 2019-01-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物 |
| US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| LT3971177T (lt) | 2016-07-20 | 2024-08-26 | Novartis Ag | Aminopiridino dariniai ir jų panaudojimas kaip selektyvių alk-2 inhibitorių |
| DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
| GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
| US11912684B2 (en) * | 2017-04-27 | 2024-02-27 | Ishihara Sangyo Kaisha, Ltd. | N-(4-pyridyl)nicotinamide compound or salt thereof |
| KR20220107213A (ko) | 2019-11-22 | 2022-08-02 | 인사이트 코포레이션 | Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법 |
| JP2023530316A (ja) | 2020-06-16 | 2023-07-14 | インサイト・コーポレイション | 貧血の治療のためのａｌｋ２阻害剤 |
| CA3195121A1 (en) * | 2020-10-09 | 2022-04-14 | Robert A. Volkmann | Heteroaryl amide inhibitors of cd38 |
| CN116099004B (zh) * | 2022-12-30 | 2024-01-30 | 深圳开悦生命科技有限公司 | Rna解旋酶dhx33抑制剂在制备用于治疗膀胱癌的药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| CN1933838A (zh) * | 2004-02-12 | 2007-03-21 | 默克公司 | 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺 |
| TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
| US20090076009A1 (en) | 2006-05-03 | 2009-03-19 | Arnould Jean-Claude Retired | Thiazole derivatives and their use as anti-tumour agents |
| WO2009030890A1 (en) | 2007-09-03 | 2009-03-12 | University Court Of The University Of Dundee | Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma |
| MX2010004491A (es) | 2007-10-25 | 2010-06-21 | Astrazeneca Ab | Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares. |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| EP2376485B1 (en) | 2008-12-19 | 2017-12-06 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| GB0903759D0 (en) | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
| AU2011208530A1 (en) * | 2010-01-19 | 2012-08-09 | Astrazeneca Ab | Pyrazine derivatives |
| BR112013029640A2 (pt) * | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
-
2012
- 2012-04-11 BR BR112013029640A patent/BR112013029640A2/pt active Search and Examination
- 2012-04-11 HR HRP20181884TT patent/HRP20181884T1/hr unknown
- 2012-04-11 KR KR1020137030982A patent/KR101581522B1/ko not_active Expired - Fee Related
- 2012-04-11 SG SG2013074638A patent/SG194105A1/en unknown
- 2012-04-11 EP EP12715279.1A patent/EP2714677B1/en active Active
- 2012-04-11 LT LTEP12715279.1T patent/LT2714677T/lt unknown
- 2012-04-11 DK DK12715279.1T patent/DK2714677T3/en active
- 2012-04-11 RS RS20181427A patent/RS58015B1/sr unknown
- 2012-04-11 CA CA2832605A patent/CA2832605C/en active Active
- 2012-04-11 AU AU2012259333A patent/AU2012259333B2/en not_active Ceased
- 2012-04-11 US US14/118,845 patent/US9273029B2/en not_active Expired - Fee Related
- 2012-04-11 SI SI201231465T patent/SI2714677T1/sl unknown
- 2012-04-11 CN CN201280025133.3A patent/CN103748086B/zh not_active Expired - Fee Related
- 2012-04-11 PL PL12715279T patent/PL2714677T3/pl unknown
- 2012-04-11 PT PT12715279T patent/PT2714677T/pt unknown
- 2012-04-11 MX MX2013012979A patent/MX352975B/es active IP Right Grant
- 2012-04-11 WO PCT/US2012/032983 patent/WO2012161877A1/en not_active Ceased
- 2012-04-11 EA EA201301302A patent/EA023364B1/ru not_active IP Right Cessation
- 2012-04-11 ES ES12715279T patent/ES2699256T3/es active Active
- 2012-04-11 JP JP2014512837A patent/JP6054954B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-04 ZA ZA2013/07429A patent/ZA201307429B/en unknown
- 2013-11-21 IL IL229528A patent/IL229528A/en active IP Right Grant
-
2016
- 2016-06-23 JP JP2016124235A patent/JP2016196492A/ja active Pending
-
2018
- 2018-03-28 JP JP2018061990A patent/JP6763904B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518884A5 (OSRAM) | ||
| JP2016196492A5 (OSRAM) | ||
| HRP20170499T1 (hr) | Derivati tiazola | |
| JP2013510124A5 (OSRAM) | ||
| JP2015529229A5 (OSRAM) | ||
| JP2015524450A5 (OSRAM) | ||
| HRP20160249T1 (hr) | Pirolidinoni kao inhibitori metap2 | |
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2010265321A5 (OSRAM) | ||
| JP2018115201A5 (OSRAM) | ||
| AR056786A1 (es) | Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com | |
| JP2010077141A5 (OSRAM) | ||
| JP2010529051A5 (OSRAM) | ||
| JP2013542247A5 (OSRAM) | ||
| WO2012122340A1 (en) | Soluble guanylate cyclase activators | |
| JP2011503103A5 (OSRAM) | ||
| JP2018538264A5 (OSRAM) | ||
| JP2010528026A5 (OSRAM) | ||
| JP2013523792A (ja) | Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ | |
| HRP20210447T1 (hr) | Piridinski spoj | |
| JP2015509075A5 (OSRAM) | ||
| JP2019500387A5 (OSRAM) | ||
| ECSP13012812A (es) | Formulaciones inmunosupresoras | |
| JP2016540811A5 (OSRAM) | ||
| NZ702618A (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |